News for Healthier Living

SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.

September 1, 2024


September 15 2024

September 14 2024

September 13 2024

September 12 2024

September 11 2024

September 10 2024

September 9 2024

September 8 2024

September 7 2024

September 6 2024

September 5 2024

September 4 2024

September 3 2024

September 2 2024